Literature DB >> 16790391

Molecular biology in colorectal cancer.

Manuel Benito1, Eduardo Díaz-Rubio.   

Abstract

Cancer is a genetic disease. Colorectal cancer is probably the type of cancer for which the most is known about the genes affected by cancer-causing mutations, their normal functions and their carcinogenic effects when mutated. Most cancer-causing mutations are somatic, occurring in the affected tissue during the course of carcinogenesis. However, most cancers also have a hereditary component that is caused by predisposing mutations that affect the germline, are heritable and contribute to the initiation of carcinogenesis. High-penetrance mutations confer predisposition to colorectal cancer mainly in Lynch syndrome (which involves mutations in mismatch-repair genes) and in familial adenomatous polyposis (which involves mutations in the APC tumour suppressor). Together, these conditions account for 5% or less of all cases of colorectal cancer. Low-penetrance mutations account for a high proportion of all the attributable risk of colorectal cancer, in both familial and sporadic cases. These mutations are more difficult to identify, but mainly due to the implementation of association studies, are increasingly being detected and characterized. The identification of both high- and low-penetrance mutations contributes significantly to our understanding of the molecular genetic processes occurring in cancer. This understanding facilitates the development of therapeutic drugs and preventive strategies.

Entities:  

Mesh:

Year:  2006        PMID: 16790391     DOI: 10.1007/s12094-006-0192-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  8 in total

Review 1.  APC dosage effects in tumorigenesis and stem cell differentiation.

Authors:  Claudia Gaspar; Riccardo Fodde
Journal:  Int J Dev Biol       Date:  2004       Impact factor: 2.203

Review 2.  A genetic model for colorectal tumorigenesis.

Authors:  E R Fearon; B Vogelstein
Journal:  Cell       Date:  1990-06-01       Impact factor: 41.582

Review 3.  Genetic predisposition to colorectal cancer.

Authors:  Albert de la Chapelle
Journal:  Nat Rev Cancer       Date:  2004-10       Impact factor: 60.716

Review 4.  An update on the genetics of colorectal cancer.

Authors:  Zoe Kemp; Cristina Thirlwell; Oliver Sieber; Andrew Silver; Ian Tomlinson
Journal:  Hum Mol Genet       Date:  2004-10-01       Impact factor: 6.150

Review 5.  Progressing toward a molecular description of colorectal cancer development.

Authors:  E R Fearon; P A Jones
Journal:  FASEB J       Date:  1992-07       Impact factor: 5.191

6.  Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer.

Authors:  M C Goyette; K Cho; C L Fasching; D B Levy; K W Kinzler; C Paraskeva; B Vogelstein; E J Stanbridge
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

7.  Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene.

Authors:  Anja Wagner; Alicia Barrows; Juul Th Wijnen; Heleen van der Klift; Patrick F Franken; Paul Verkuijlen; Hidewaki Nakagawa; Marjan Geugien; Shantie Jaghmohan-Changur; Cor Breukel; Hanne Meijers-Heijboer; Hans Morreau; Marjo van Puijenbroek; John Burn; Stephany Coronel; Yulia Kinarski; Ross Okimoto; Patrice Watson; Jane F Lynch; Albert de la Chapelle; Henry T Lynch; Riccardo Fodde
Journal:  Am J Hum Genet       Date:  2003-03-25       Impact factor: 11.025

Review 8.  Molecular models for the tissue specificity of DNA mismatch repair-deficient carcinogenesis.

Authors:  Elizabeth C Chao; Steven M Lipkin
Journal:  Nucleic Acids Res       Date:  2006-02-06       Impact factor: 16.971

  8 in total
  6 in total

Review 1.  Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target.

Authors:  Jieru E Lin; Peng Li; Giovanni M Pitari; Stephanie Schulz; Scott A Waldman
Journal:  Future Oncol       Date:  2009-05       Impact factor: 3.404

2.  Combination of lactate calcium salt with 5-indanesulfonamide and α-cyano-4-hydroxycinnamic acid to enhance the antitumor effect on HCT116 cells via intracellular acidification.

Authors:  Keun-Yeong Jeong; Poonam Mander; Jae Jun Sim; Hwan Mook Kim
Journal:  Oncol Lett       Date:  2016-01-20       Impact factor: 2.967

3.  What does the population attributable fraction mean?

Authors:  Beverly Levine
Journal:  Prev Chronic Dis       Date:  2006-12-15       Impact factor: 2.830

4.  Up-regulation and clinical relevance of novel helicase homologue DHX32 in colorectal cancer.

Authors:  Chunling Huang; Xianming Liang; Ruxin Huang; Zhongying Zhang
Journal:  J Exp Clin Cancer Res       Date:  2009-01-22

5.  Deletion hotspots in AMACR promoter CpG island are cis-regulatory elements controlling the gene expression in the colon.

Authors:  Xiang Zhang; Irwin Leav; Monica P Revelo; Ranjan Deka; Mario Medvedovic; Zhong Jiang; Shuk-Mei Ho
Journal:  PLoS Genet       Date:  2009-01-16       Impact factor: 5.917

6.  Spatial analysis of colorectal cancer incidence and proportion of late-stage in Massachusetts residents: 1995-1998.

Authors:  Laurie M DeChello; T Joseph Sheehan
Journal:  Int J Health Geogr       Date:  2007-06-04       Impact factor: 3.918

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.